Latigo Biotherapeutics' non-opioid LTG-001 reduced acute pain in Phase 2b, competing with Vertex's Journavx; Phase 3 trial planned for late 2026.
Latigo Biotherapeutics said its non-opioid drug reduced acute pain in a Phase 2b study, as the company seeks to compete with Vertex Pharmaceuticals’ approved pain …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Latigo Biotherapeutics published positive data for an acute-pain drug meant to rival a Vertex medicine already on the market
Latigo Biotherapeutics Announces New England Journal of Medicine Publication of Positive LTG-001 Abdominoplasty Clinical Trial…
The Westlake-founded company specializes in non-opioid drugs that target sodium ion channels, and is now adding to what’s already…
Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?
Novel analgesic associated with significantly lower opioid use
FDA approves Viridian's Lumvoa for thyroid eye disease, launching competition with Amgen's $1.9B Tepezza on efficacy and infusion…
Latigo reports mid-stage success for would-be rival to Vertex’s pain drug Journavx
Latigo Biotherapeutics Announces New England Journal of Medicine Publication of Positive LTG-001 Abdominoplasty Clinical Trial Results in Moderate-to-Severe Acute Pain
Sodium Channel Blocker Cuts Post-Surgery Pain
PVP Labs Selected to Present Taphalgin® (Lumekefamide) as a Novel Battlefield Pain Solution at 2026 MHSRS
Pfizer takes Litfulo to regulators in vitiligo challenge to Incyte, AbbVie
Xpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosis
On 4th try, Outlook scores FDA nod for reformulated version of Roche's Avastin for AMD
